Botanix Pharmaceuticals Ltd (BOT) - Total Liabilities
Based on the latest financial reports, Botanix Pharmaceuticals Ltd (BOT) has total liabilities worth AU$47.80 Million AUD (≈ $33.82 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Botanix Pharmaceuticals Ltd (BOT) equity growth momentum to track the company's year-over-year net asset growth rate.
Botanix Pharmaceuticals Ltd - Total Liabilities Trend (1989–2025)
This chart illustrates how Botanix Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. See Botanix Pharmaceuticals Ltd (BOT) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Botanix Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Botanix Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CIFI Holdings (Group) Co. Ltd
F:6CI
|
Germany | €196.91 Billion |
|
Derwent London PLC
LSE:DLN
|
UK | GBX1.70 Billion |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
USA | $3.66 Million |
|
Bintai Kinden Corporation Bhd
KLSE:6998
|
Malaysia | RM161.31 Million |
|
Sapmer
PA:ALMER
|
France | €75.71 Million |
|
Dominant Enterprise Bhd
KLSE:7169
|
Malaysia | RM357.00 Million |
|
Goldbank Mining Corp
V:GLB
|
Canada | CA$18.02 Million |
|
Wiseway Group Ltd
AU:WWG
|
Australia | AU$64.78 Million |
Liability Composition Analysis (1989–2025)
This chart breaks down Botanix Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Botanix Pharmaceuticals Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Botanix Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Botanix Pharmaceuticals Ltd (1989–2025)
The table below shows the annual total liabilities of Botanix Pharmaceuticals Ltd from 1989 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$47.80 Million ≈ $33.82 Million |
+1180.69% |
| 2024-06-30 | AU$3.73 Million ≈ $2.64 Million |
+97.99% |
| 2023-06-30 | AU$1.88 Million ≈ $1.33 Million |
-67.97% |
| 2022-06-30 | AU$5.89 Million ≈ $4.16 Million |
+411.76% |
| 2021-06-30 | AU$1.15 Million ≈ $813.76K |
-31.31% |
| 2020-06-30 | AU$1.67 Million ≈ $1.18 Million |
-63.48% |
| 2019-06-30 | AU$4.58 Million ≈ $3.24 Million |
+221.60% |
| 2018-06-30 | AU$1.43 Million ≈ $1.01 Million |
+202.93% |
| 2017-06-30 | AU$470.60K ≈ $332.98K |
-8.77% |
| 2016-06-30 | AU$515.83K ≈ $364.98K |
+463.23% |
| 2015-06-30 | AU$91.58K ≈ $64.80K |
-70.44% |
| 2014-06-30 | AU$309.85K ≈ $219.24K |
-87.65% |
| 2013-06-30 | AU$2.51 Million ≈ $1.78 Million |
+6.71% |
| 2012-06-30 | AU$2.35 Million ≈ $1.66 Million |
+3.42% |
| 2011-06-30 | AU$2.27 Million ≈ $1.61 Million |
+22.57% |
| 2010-06-30 | AU$1.86 Million ≈ $1.31 Million |
+62.88% |
| 2009-06-30 | AU$1.14 Million ≈ $805.90K |
+5.28% |
| 2008-06-30 | AU$1.08 Million ≈ $765.47K |
+79.27% |
| 2007-06-30 | AU$603.47K ≈ $427.00K |
+112.57% |
| 2006-06-30 | AU$283.89K ≈ $200.87K |
+27.17% |
| 2005-06-30 | AU$223.25K ≈ $157.96K |
+22.92% |
| 2004-06-30 | AU$181.62K ≈ $128.50K |
-37.22% |
| 2003-06-30 | AU$289.29K ≈ $204.69K |
-36.82% |
| 2002-06-30 | AU$457.88K ≈ $323.98K |
+170.40% |
| 2001-06-30 | AU$169.34K ≈ $119.82K |
+43.51% |
| 2000-06-30 | AU$118.00K ≈ $83.49K |
-98.54% |
| 1999-06-30 | AU$8.06 Million ≈ $5.71 Million |
-44.80% |
| 1998-06-30 | AU$14.61 Million ≈ $10.34 Million |
-19.80% |
| 1997-06-30 | AU$18.22 Million ≈ $12.89 Million |
-4.79% |
| 1996-06-30 | AU$19.13 Million ≈ $13.54 Million |
-35.62% |
| 1995-06-30 | AU$29.72 Million ≈ $21.03 Million |
+31.96% |
| 1994-06-30 | AU$22.52 Million ≈ $15.94 Million |
+14.41% |
| 1993-06-30 | AU$19.68 Million ≈ $13.93 Million |
+35.61% |
| 1992-06-30 | AU$14.52 Million ≈ $10.27 Million |
-0.16% |
| 1991-06-30 | AU$14.54 Million ≈ $10.29 Million |
+6.72% |
| 1990-06-30 | AU$13.62 Million ≈ $9.64 Million |
+15.26% |
| 1989-06-30 | AU$11.82 Million ≈ $8.36 Million |
-- |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more